Download PDF
CC BY-NC-ND 4.0 · South Asian J Cancer 2014; 03(01): 071-073
DOI: 10.4103/2278-330X.126534
ONCOLOGY REFLECTIONS

Counterpoint: Angelina's choice-or the choice of anyone else in her place

P. M. Parikh
Department of Medicine, Indian Cancer Society, Mumbai, Maharashtra
› Author Affiliations Source of Support: Nill.
› Further Information
  PDF Download Permissions and Reprints


Publication History

Article published online:
31 December 2020

© 2014. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Goel NS. Angelina′s choice. South Asian J Cancer 2013;2:285-7.
  • 2 Jones NB, Wilson J, Kotur L, Stephens J, Farrar WB, Agnese DM. Contralateral prophylactic mastectomy for unilateral breast cancer: An increasing trend at a single institution. Ann Surg Oncol 2009;16:2691-6.
  • 3 Zagouri F, Chrysikos DT, Sergentanis TN, Giannakopoulou G, Zografos CG, Papadimitriou CA, et al. Prophylactic mastectomy: An appraisal. Am Surg 2013;79:205-12.
  • 4 National Comprehensive Cancer Network (NCCN) updated breast cancer guidelines. Available from: http://www. infoonco.es/wp-content/uploads/2011/10/breast_cancer_2.2013.pdf [Last accessed on 2013 Sept 24].
  • 5 Alkner S, Bendahl PO, Fernö M, Nordenskjöld B, Rydén L. South Swedish and South-East Swedish Breast Cancer Groups. Tamoxifen reduces the risk of contralateral breast cancer in premenopausal women: Results from a controlled randomised trial. Eur J Cancer 2009;45:2496-502.
  • 6 Phillips KA, Milne RL, Rookus MA, Daly MB, Antoniou AC, Peock S, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2013;31:3091-9.
  • 7 National Cancer Institute. Genetics of breast and ovarian cancer. Available from: http://www.cancer.gov/cancertopics/pdq/genetics/breast-and ovarian/HealthProfessional/page3 [Last accessed on 2013 Sep 23].
  • 8 Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA. Increasing use of contralateral prophylactic mastectomy for breast cancer patients: A trend toward more aggressive surgical treatment. J Clin Oncol 2007;25:5203-9.
  • 9 Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:159-64.
  • 10 Peled AW, Irwin CS, Hwang ES, Ewing CA, Alvarado M, Esserman LJ. Total skin-sparing mastectomy in BRCA mutation carriers. Ann Surg Oncol 2013.
  • 11 Font-Gonzalez A, Liu L, Voogd AC, Schmidt MK, Roukema JA, Coebergh JW, et al. Inferior survival for young patients with contralateral compared to unilateral breast cancer: A nationwide population-based study in the Netherlands. Breast Cancer Res Treat 2013;139:811-9.
  • 12 Arrington AK, Jarosek SL, Virnig BA, Habermann EB, Tuttle TM. Patient and surgeon characteristics associated with increased use of contralateral prophylactic mastectomy in patients with breast cancer. Ann Surg Oncol 2009;16:2697-704.
  • 13 Yi M, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera GV, et al. Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy. Cancer 2009;115:962-71.
  • 14 Jensen JA, Lin JH, Kapoor N, Giuliano AE. Surgical delay of the nipple-areolar complex: A powerful technique to maximize nipple viability following nipple-sparing mastectomy. Ann Surg Oncol 2012;19:3171-6.
  • 15 Metcalfe KA, Semple JL, Narod SA. Satisfaction with breast reconstruction in women with bilateral prophylactic mastectomy: A descriptive study. Plast Reconstr Surg 2004;114:360-6.
  • 16 Munshi A, Gupta S, Anderson B, Yarnold J, Parmar V, Jalali R, et al. Guidelines for locoregional therapy in primary breast cancer in developing countries: The results of an expert panel at the 8(th) Annual Women′s Cancer Initiative-Tata Memorial Hospital (WCI-TMH) Conference. Indian J Med Paediatr Oncol 2012;33:112-22.
  • 17 Matloff ET, Bonadies DC, Moyer A, Brierley KL. Changes in specialists′ perspectives on cancer genetic testing, prophylactic surgery and insurance discrimination: Then and now. J Genet Couns2013.
  • 18 Matloff ET, Shappell H, Brierley K, Bernhardt BA, McKinnon W, Peshkin BN. What would you do? Specialists′ perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination. J Clin Oncol 2000;18:2484-92.
  • 19 Singh K, Lester J, Karlan B, Bresee C, Geva T, Gordon O. Impact of family history on choosing risk-reducing surgery among BRCA mutation carriers. Am J Obstet Gynecol 2013;208:329.e1-6.
  • 20 Parikh PM, Prabhash K, Bhattacharyya GS, Ranade AA. The patient′s personality as a guide to communication strategy. In: Surbone A, Zwitter M, Rajer M, Stiefel R, editors. New Challenges in Communication with Cancer Patients. Vol. 11. Berlin: Springer; 2012. p. 137-43.